Management
The role of CEO is, subordinate to the Board of Directors and its main task is to carry out the daily management of Xbrane and the daily activities of the Company. The Board of Director’s rules of procedure and instructions for the CEO stipulate for which matters the Board of Directors is responsible to decide upon, and which decisions fall within the CEO’s area of responsibility. The CEO is also responsible for producing reports and necessary data for decision-making ahead of Board meetings and for presenting the material at Board meetings.
Xbrane has a management team consisting of six people, which in addition to the CEO/Head of Investor Relations is comprised of the CFO, COO/Head of Biosimilars, COO/Head of Long-acting injectables, CTO and Head of Clinical affairs.
| Name | Position | Member of the senior management since | Employed at the Company since | Holdings in Xbrane | ||
|---|---|---|---|---|---|---|
| Shares | Warrants | Convertibles | ||||
| Martin Åmark | CEO/Head of Investor Relations | 2015 | 2015 | 152,896 | 24,000 | – |
| Susanna Helgesen | CFO | 2017 | 2017 | 12,136 | 24,000 | – |
| Siavash Bashiri | COO/Head of Biosimilars | 2012 | 2012 | 102,175 | 7,000 | – |
| Paolo Sarmientos | COO/Head of Long-acting injectables | 2015 | 2015 | 296,939 | – | 74,054 |
| David Vikström | CTO | 2014 | 2014 | 32,055 | 24,000 | – |
| Dina Jurman | Head of Clinical affairs | 2017 | 2017 | 420 | – | – |